Annexin Pharmaceuticals AB (publ) (STO:ANNX)
Sweden flag Sweden · Delayed Price · Currency is SEK
14.20
-0.70 (-4.70%)
Feb 11, 2026, 12:17 PM CET

STO:ANNX Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
10.079.598.0112.2910.7
Research & Development
26.2440.8136.0328.3742.13
Operating Expenses
36.3150.444.0440.6652.83
Operating Income
-36.31-50.4-44.04-40.66-52.83
Interest Expense
----0-1.86
Interest & Investment Income
0.470.230.12--
Earnings From Equity Investments
----0.95
Currency Exchange Gain (Loss)
-1.05-0.08-0.14-0.071.59
Other Non Operating Income (Expenses)
--0---
Pretax Income
-36.89-50.25-44.05-40.73-52.14
Net Income
-36.89-50.25-44.05-40.73-52.14
Net Income to Common
-36.89-50.25-44.05-40.73-52.14
Shares Outstanding (Basic)
75211
Shares Outstanding (Diluted)
75211
Shares Change (YoY)
46.31%170.59%14.23%78.30%33.40%
EPS (Basic)
-5.58-11.11-26.36-27.84-63.55
EPS (Diluted)
-5.58-11.11-26.36-27.84-63.55
Free Cash Flow
-37.05-50.23-43.4-41.17-45.02
Free Cash Flow Per Share
-5.60-11.11-25.97-28.14-54.88
EBITDA
-36.12-50.2-43.85-40.46-52.63
D&A For EBITDA
0.190.190.190.190.19
EBIT
-36.31-50.4-44.04-40.66-52.83
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.